Yun, E.J., Zhou, J., Lin, C-H., Hernandez, E., Fazli, L., Gleave,, Hsieh, J.T. (2016) Targeting cancer stem cell in castration resistant prostate cancer. Clin. Cancer Res., 22:670-679. PMID26876207
Zhou, J.C., Zhu, G., Huang, J., Li, L., Du, Y., Gao, Y., Wu, D., Wang, X., Hsieh, J.T., He, D., Wu K. (2016) Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Lett. 370:313-23.
Yu, M., Zhou, J., Du, B., Ning, X., Authement, C., Gandee, L., Kapur, P., Hsieh, J.T., Zheng, J. (2016) Noninvasive staging of kidney dysfunction enabled by renal clearable luminescent gold nanoparticles nanofluorophores. Angewandte Chemie, 55: 2787-2791. PMID26800513 PMCID4834218
Kumar, A., Mastren, T.,Wang, B., Hsieh, J.T., Hao, G., Sun, X. (2016) Design of Small-molecule Drug Conjugates for Prostate Cancer Targeted Theranostics. Bioconjug. Chem., 27:1681-1699. PMID27248781
Zhou, J., Wu, K., Luo, J., Yun, E.J., Kapur, P., Pong, R.C., Du, Y., Wang, B., Authement, C., Hernandez, E., Jichen Yang, J., Xiao, G., Cha, T-L., Wu, H-C., Wu, D., Margulis, V., Lotan, Y., Brugarolas, J., He, D., Hsieh, T. (2016) Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene, 35:4663-4674. PMID26876207
Wang, Z-R., Wei,H., Zhou , J.C., Haddad, A., Zhao, L.Y., Kapur, P., Wu, K., Wang, B., Yu, Y-H., Liao, B., He, D., Chen, W., Margulis, V., Hsieh, J.T., Luo, J-H.. (2016) Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget, 7:31508-31519. PMID27129174.
Huang, J., Wang, B., Hui, K., Zeng, J., Fan, J., Wang, X., Hsieh, J.T., He, D., Wu, K. (2016) miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion. Rep., 36:1693-1701. PMID27430302
Wang, B., Huang, J., Zhou, J., Hui, K., Xu, S., Fan, J., Li, L., Wang, X., Hsieh, J.T., He, D., Wu, K. (2016) DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cell. Signaling, 28:1623-1630. PMID27476001
Yu, L., Shang, Z.F., Abdisalaam, S., Lee, K.J., Gupta, A., Hsieh, J.T., Aroumougame, A., Chen, B., Saha, D. (2016) Tumor Suppressor Protein DAB2IP Participates in Chromosomal Stability Maintenance through Activating Spindle Assembly Checkpoint and Stabilizing Kinetorchore-Microtubule Attachments. Nucleic Acids Res., 44:8842-8854. PMID27568005
Huang, P-H., Chen, M-C., Lai, C.H. Hsieh, J.T., Wang, J-H., Peng, Y-T., Lee, Y., Lin , E., Yue, C-H., Wang, H-Y., You, S-C., Lin, H. (2016) Cdk5 directly targets nuclear p21CIP1 and promotes cancer cell growth. Cancer Res., 76:6888-6900. PMID27909065
Huang, W.Y., Lin, J.N., Hsieh, J.T., Chou, S.C., Lai, C.H., Yun, E.J., Lo, U., Pong, R.C., Lin, J.H., Lin, Y.H. (2016) Nanoparticle targeting CD44-positive cancer cells for Site-specific drug delivery in prostate cancer therapy. ACS Appl. Mater. Interfaces, 8:30722-30734. PMID27786455
Chen, W., Zhou, J., Wu, K., Huang, J., Ding, Y., Yun, E-J., Wang, B., Ding, , Hernandez, E., Santoyo, J., Chen, H., Lin, H., Sagalowsky, A., He, D., Zhou, J., Hsieh, J.T. (2016) Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. Oncotarget, 7:56842-56854. PMID27472396
Chen, Y.A., Lien, H.M., Kao, M.C., Lo, U., Lin, L.C., Lin, C. J., Chang, S.J., Chen, C.C., Tang, C.H., Lin, H., Hsieh, J.T., Lai C.H. (2016) Sensitization of radioresistant prostate cancer cells by resveratrol isolated from Arachis hypogaea stems. PLoS One, 12:e0169204. PMID28081154
Lai, C.K., Chen, A., J.C., Lin, C.J., Kao, M.C., Huang, M.Z., Lin, Y.H., Chuan C.N., Lo, U., Lin, L.C., Lin, H., Hsieh, J.T., Lai, C.H. (2016) Molecular mechanisms of interactions between membrane cholesterol and cytolethal distending toxin in Campylobacter jejuni. Front. Cell. Infect. Microbiol., 6:1-8.
Liu, L., Xu, C., Hsieh, J.T., Gong, J., Xie, D. (2016) DAB2IP in cancer. Oncotarget 7:3766-3776. PMID26658103
Yun, E., Lo, U., Hsieh, J.T. (2016) The evolving landscape of prostate cancer stem cell (PCSC): therapeutic implications and future challenges. Asian J. Urol., 3:203-210. PMID29264188
Lin, L-C., Gao, A.C., Lai, C.H., Hsieh, J.T., Lin, H. (2017) Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) through exosomes released from adjacent cancer cells. Cancer Letters, 391:74-82. PMID28109910
Hui, K., Gao, Y., Huang, J., Xu, S., Wang, B., Zeng, J., Fan, J., Wang, X., Yue, Y., Wu, S., Hsieh, J.T., He, D., Wu, K. (2017) RASAL2, a RAS GTPase activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis., 8:e2600. PMID28182001
Zhou, J., Yun, E.J., Chen, W., Ding, Y., Wu, K., Wang, B., Ding, C., Elizabeth Hernandez, E., Santoyo, J., Pong, R.C., Chen, H., He, D., Zhou, J., Hsieh, J.T. (2017) Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogues. Cell Death Dis., 8:e2701. PMID28333136
Yun, E.J., Zhou, J., Lin, C-J., Hernandez, E., Santoyo, , Hernandez, E., Lai, C-H., Lin, H., He, D., Hsieh, J.T. (2017) The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes. Oncotarget, 8:66975-66986. PMID28537931
Miao, L., Yang, L., Li, R., Nava Rodrigues D., Crespo, M., Hsieh, J.T., Tilley, W.D., de Bono, J.S., Selth, L.A., Raj, G.V. (2017) Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Res., 77:3101-3112. PMID28302679
Wang, B., Lo, U., Wu, , Kapur, P., Liu, X., Huang, J., Chen, W., Hernandez, E., John Santoyo, J., Ma, S-H., Pong, R-C., He, D., Cheng, Y-Q., Hsieh, J.T. (2017) Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. International J Cancer, 141: 2121-2130. PMID28722220
Xie, Z., Su, Y., Selvi, E., Kim, G.B., Ma, C., Aragon-Sanabna, V., Dong, C., Hsieh, J.T., Yang J. (2017) Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery. Small, 13:1603121-1603130. PMID28026115
Xu, , Yu, M., Carter, P., Hernandez, E., Dang, A., Kapur, P., Hsieh, J.T., Zheng, J. (2017) In Vivo X-ray Imaging of Transport of Renal Clearable Gold Nanoparticles in the Kidneys. Angewandte Chemie, 56:13356-13360. PMID28881491
Lo, U., Lee, C.F., Lee, M.S., Hsieh, J.T. (2017) The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int. J. Mol. Sci., 18: pii: E2079. PMID28973968
Shan, D., Hsieh, J.T., Bai, X., Yang, J. (2018) Citrate-based fluorescent biomaterials. Adv Healthc Mater. e1800532. PMID30047618
Tai, Y.L, Chen, K.C., Hsieh, J.T., Shen, T.L. (2018) Exosomes in cancer development and clinical applications. Cancer Sci., 109:2364-2374. PMID29908100
Xu, J., Yu, M., Peng, C., Carter, P., Tian, J., Ning, X., Zhou, Q., Tu, Q., Zhang, G., Dao, A., Jiang, X., Kapur, P., Hsieh, J.T., Zhao, X., Liu, P., Zheng, J. (2018) Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles: From Mice to Non-human Primates. Angewandte Chemie, 56:266-271. PMID29160029
Cai, H., Xie, F., Mulgaonkar, A., Chen, L., Sun, X., Hsieh, J.T., Peng, F., Tian, R., Li, L., Wu, C., Ai, H. (2018) Bombesin functionalized 64Cu-copper sulfide nanoparticles for targeted imaging of orthotopic prostate cancer. Nanomedicine, doi: 10.2217. PMID29786467
Hui, K, Wu, S, Yue, Y, Gu, Y, Guan, B, Wang, X, Hsieh, JT, Chang, LS, He, D, Wu, K. (2018) RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer. Cell Signal., 48:38-44. PMID9702203
Zhu J, Huang Z, Zhang M, Wang W, Liang H, Zeng J, Wu K, Wang X, Hsieh JT, Guo P, Fan J. (2018) HIF-1α promotes ZEB1 expression and EMT in a human bladder cancer lung metastasis animal model. Oncol Lett., 15:3482-3489. PMID29467870
Hui, K., Yue, Y, Wu, S,, Gu, Y, Guan, B, Wang, X, Hsieh, JT, Chang, LS, He, D, Wu, K. (2018) The expression and function of RASAL2 in renal cell carcinoma angiogenesis. Cell Death Dis., 9:881. PMID30158581
Wang, B., Gu, Y., Hui, K., Huang, J., Xu, S., Wu, S, Li, L., Fan, J., Wang, X., Hsieh, J.T., He, D., Wu, , (2018) AKR1C3, a crucial steroidogenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Urol Oncol., 36:472.e11-20. PMID30139661